Key data points from the William Blair biopharma investment banking group’s Quarterly Rx report was featured in Axios as part of its coverage of the sector’s IPO and M&A market at the close of 2025’s first quarter.
“The sector ends Q1 with ‘existential anxieties’ amid mostly anemic dealmaking activity, says a recent William Blair report,” the article wrote.